↓ Skip to main content

Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study

Overview of attention for article published in International Journal of Impotence Research, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
2 news outlets
twitter
1 X user
patent
4 patents
video
1 YouTube creator

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
21 Mendeley
Title
Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study
Published in
International Journal of Impotence Research, December 2015
DOI 10.1038/ijir.2015.22
Pubmed ID
Authors

J Twidwell, L Levine

Abstract

Safety and efficacy of topically applied gel H-100 composed of Nicardipine, superoxide dismutase and emu oil for treatment of acute phase Peyronie's disease (PD) was evaluated. Twenty-two patients (PD <12 months duration) were studied in a prospective, randomized, double-blind, placebo-controlled study. Eleven patients received H-100 and 11 patients received placebo for 3 months. All 22 patients then received H-100 for the final 3 months. Flaccid-stretched penile length, degree of penile curvature, pain level and side effects were assessed monthly. H-100 showed significant improvement in all PD parameters at 6 months: mean stretched penile length increase (22.6%, P=0.0002), mean curvature reduction (40.8%, P=0.0014), and mean pain level reduction (85.7%, P=0.004). Placebo group showed no significant improvement except for mean stretched penile length increase (6.8%, P=0.009). Crossover patients from placebo to H-100 showed significant improvement in all parameters: mean stretched penile length increase (17.5%, P=0.000007), mean curvature reduction (37.1%, P=0.006), and mean pain level reduction (40%, P=0.17). Treatment was well tolerated. A self-limited rash was the only side effect in three patients. Statistically significant improvements in flaccid-stretched penile length, curvature and pain suggest that H-100 is a safe and possibly effective non-invasive, topically applied treatment for acute phase Peyronie's Disease.International Journal of Impotence Research advance online publication, 24 December 2015; doi:10.1038/ijir.2015.22.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Other 4 19%
Student > Bachelor 3 14%
Student > Master 2 10%
Student > Doctoral Student 1 5%
Researcher 1 5%
Other 2 10%
Unknown 8 38%
Readers by discipline Count As %
Medicine and Dentistry 9 43%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Unknown 11 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 24. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2023.
All research outputs
#1,450,039
of 23,845,863 outputs
Outputs from International Journal of Impotence Research
#111
of 1,254 outputs
Outputs of similar age
#25,996
of 395,363 outputs
Outputs of similar age from International Journal of Impotence Research
#1
of 8 outputs
Altmetric has tracked 23,845,863 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,254 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.4. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 395,363 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them